Drug profile · INN
binimetinib
MEKTOVI
binimetinib (MEKTOVI) is a dual specificity mitogen-activated protein kinase kinase 1 inhibitor. Associated with Pierre Fabre Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — binimetinib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 6
- Programs
- 15
- Data quality
- 0.89
Quick answer
binimetinib (MEKTOVI) is a dual specificity mitogen-activated protein kinase kinase 1 inhibitor. Associated with Pierre Fabre Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
Primary target: Dual specificity mitogen-activated protein kinase kinase 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12252511
Process for the preparation of cyclic depsipeptides
granted -
US 11739123
Process for the preparation of cyclic depsipeptides
granted -
US 11053284
Process for the preparation of cyclic depsipeptides
granted -
US 10689419
Process for the preparation of cyclic depsipeptides
granted -
US 10100089
Process for the preparation of cyclic depsipeptides
granted -
US 9523691
Use of the olfactomedin-4 protein (OLFM4) in colorectal cancer diagnosis
granted
Frequently asked questions
What is binimetinib?
binimetinib (MEKTOVI) is a dual specificity mitogen-activated protein kinase kinase 1 inhibitor. Associated with Pierre Fabre Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for binimetinib?
MEKTOVI is a marketed brand name for binimetinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of binimetinib?
binimetinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.